Algifor-L is authorized for the symptomatic management of a variety of common acute conditions. Its primary benefit is to help relieve pain, reduce inflammation, and address fever. The medication may be used for the short-term relief of discomfort associated with various clinical scenarios.

Common uses include providing support for pain related to headache, toothache, and discomfort following minor injuries. It also helps manage musculoskeletal issues, such as back pain, and is indicated for the relief of menstrual pain (dysmenorrhea). Furthermore, Algifor-L is used for its action in reducing fever associated with flu-like states. Addressing these symptoms can support the patient’s comfort and maintenance of daily activities during acute episodes.

Quick Fact: Relief for Acute Discomfort

The medication focuses on the temporary relief of symptoms, aiding patient comfort during short-term, painful episodes.

Eligibility Map: Who Can and Cannot Use Algifor-L — Official Regulatory Information

The official regulatory documents define the strict population eligibility for Algifor-L (Ibuprofen L-Lysinate) through three core classifications: permitted use, use with caution, and absolute contraindication.

---

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and Adolescents, typically ge 12 years of age and ge 40 kg body weight.
Populations for whom use is contraindicated	History of NSAID hypersensitivity or recurrent peptic ulcer/haemorrhage. Severe failure of heart (NYHA Class IV), renal, or hepatic function. Use during the third trimester of pregnancy.
Eligibility-related restrictions	Older adults and patients with mild to moderate organ impairment or established cardiovascular disease require mandated caution and lowest effective dose.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with severe impairment of heart, liver, or kidney function.
• Use is prohibited for individuals with a history of recurrent gastrointestinal bleeding or NSAID-induced hypersensitivity.
• It is contraindicated during the third trimester of pregnancy and not recommended for children under 12 years of age.

Connection to the overall eligibility profile

Regulatory authorities establish these rules by setting absolute bans for populations with specific severe conditions or a history of adverse events. For other vulnerable groups, such as older adults and those with mild organ dysfunction, regulatory documents mandate conditional use with specific warnings present in the labeling.

Interactions with other medicines and products

The interaction profile for Algifor-L (Ibuprofen L-Lysinate) is governed by officially documented patterns that establish combination restrictions and administration requirements.

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is formally advised against due to an established, additive risk of serious gastrointestinal toxicity, such as bleeding and perforation. Similarly, combination with Anticoagulants, Oral Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs) carries an officially documented, additive risk of bleeding and ulceration.

A specific timing rule applies when co-administering with low-dose Aspirin used for cardioprotection, as Ibuprofen may competitively inhibit its antiplatelet effect. Ibuprofen must be taken at least 30 minutes after or at least 8 hours before the Aspirin dose.

Exposure modification is documented with substances like Lithium, Digoxin, and high-dose Methotrexate, where Ibuprofen may increase the plasma concentrations of these medicines through altered clearance. Furthermore, co-use with Alcohol is associated with an increased occurrence of adverse effects in the gastrointestinal and central nervous systems. Official labeling also notes that the elderly population is particularly susceptible to the severe outcomes of these documented GI risk interactions.

Targeted Inhibition of the Cyclooxygenase Pathway

The fundamental mechanism involves the reversible competitive inhibition of the Cyclooxygenase (COX) enzymes. The active moiety, Ibuprofen, binds to the catalytic sites of both COX-1 and COX-2 isoforms, thereby blocking the conversion of the substrate arachidonic acid into prostanoids. This molecular action results in a substantial reduction in the synthesis of prostaglandins, which are chemical mediators associated with nociceptive and inflammatory pathways.

---

Dual Central and Peripheral Physiological Modulation

This mechanism exerts influence in two primary anatomical domains. Peripherally, the reduction of prostaglandins decreases the sensitization of nerve endings, which limits the signaling of nociceptors. Centrally, the same mechanism within the hypothalamus facilitates the downward resetting of the central temperature set point. This simultaneous central and peripheral modulation defines the comprehensive physiological scope of the mechanism.

---

Formulation-Driven Acceleration of Mechanism Onset

The L-Lysinate component, a highly soluble salt, has no direct pharmacodynamic activity on COX enzymes. However, this formulation significantly accelerates the rate of systemic absorption of Ibuprofen. This enhanced pharmacokinetic profile facilitates the more rapid achievement of the necessary inhibitory concentration at the target enzymes, enabling the core COX inhibition mechanism to engage sooner.

How to Use Algifor-L: Official Administration Guidelines

Algifor-L (Ibuprofen L-Lysinate) is intended for oral administration only, available in dosage forms such as film-coated tablets and granules for oral solution. The official usage instructions dictate a standardized approach based on minimum effective dose and strict timing, as detailed in the product's prescribing information.

---

Administration Scope

Instruction	Detail
Route of Administration	Oral administration (swallowed) is the only approved route for this form.
Standard Dosing	The initial single dose is typically 200 mg to 400 mg Ibuprofen equivalent.
Maximum Daily Dose	The total daily dose for self-medication must not exceed 1200 mg Ibuprofen equivalent in 24 hours.
Dose Interval	Doses must be separated by a minimum of 4 to 6 hours to prevent exceeding the recommended limits.
Contextual Intake	Tablets should be swallowed whole with water. Taking the medicine with food is advised for individuals who have a history of a sensitive stomach.

---

Procedural Use and Limits

Classification	Detail
Adolescent Use	Adolescents (from 12 years of age or weighing 40 kg or more) follow the standard adult dosing guidelines.
Short-Term Constraint	Use is strictly limited to a short course; for self-treatment, it should not exceed 3 consecutive days for fever or 4 consecutive days for pain without consultation.
Core Principle	Always use the lowest effective dose for the shortest duration necessary to achieve the desired effect.

---

This protocol ensures the administration method, dosing range, and time constraints are adhered to according to the product's official specifications.

Evidence for Pain and Fever Relief

Research examined this medicine in short-term, single-dose Randomized Controlled Trials (RCTs) applied to conditions associated with acute or disruptive episodes, such as headache, menstrual pain, and post-dental surgery. Studies monitored patient-reported outcomes, including pain intensity and the need for rescue analgesic medication. Evidence derived from these settings, including systematic reviews that synthesize data (often focusing on the base compound, Ibuprofen), describes how symptoms evolved in the observed populations. However, findings were mixed when studies explored differences in the time to onset of perceived discomfort compared to standard Ibuprofen in the clinical setting, and follow-up durations were restricted to a few hours post-dose.

---

Research on the Ibuprofen L-Lysinate Formulation

Specialized Pharmacokinetic (PK) and bioavailability trials were conducted in healthy adults to assess the drug's absorption profile. Studies monitored outcomes such as the time required to reach the peak concentration (Tmax). Data show patterns related to a difference in the time required to reach Tmax for the Lysinate salt formulation when compared to the standard Ibuprofen acid in a fasted state. However, trials also described patterns where this measured difference in absorption was attenuated when the medicine was taken after a meal, meaning the rate of absorption is influenced by food intake.

---

Evidence Gaps and Research Duration

The clinical relevance of the measured difference in absorption speed is not fully established across all acute pain conditions. The majority of trials focus on episodes where symptoms become more noticeable, and long-term effects are not fully established based on the primary studies for this formulation, as follow-up durations were limited. Furthermore, data for certain specialized groups, such as children and older adults, remain insufficient in the published RCTs.

Common questions about Algifor-L (FAQ)

---

Q: How long does the pain-relieving effect of Algifor-L last?

Regulatory information for the active compound indicates that the pain-relieving effect typically lasts between four and six hours per dose. The official dosing recommendations suggest doses be separated by a minimum time, which aligns with the typical duration of effect.

---

Q: Can Algifor-L be taken by people who have asthma?

Official product information states that the medicine is generally restricted for individuals who have previously experienced hypersensitivity reactions, such as asthma or hives, after taking Ibuprofen, aspirin, or other similar non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: Can I take Algifor-L if I am already taking paracetamol (acetaminophen)?

Regulatory documents advise against taking this medicine simultaneously with other products that contain paracetamol or other ibuprofen-containing medicines. The guidance is intended to help prevent the risk of overdose and potential toxicity, according to official labeling.

---

Q: Is there a risk of interaction between Algifor-L and alcohol?

Official labeling documents that combining this medicine with alcohol has been associated with an increased occurrence of adverse effects. These effects may impact the gastrointestinal system and the central nervous system.

---

Q: Can Algifor-L be used for period pain (menstrual cramps)?

The active compound is described in official documents as indicated for the relief of pain and inflammation associated with primary dysmenorrhoea (menstrual cramps).

---

Q: Is Algifor-L effective for headaches or migraines?

The medicine is generally indicated in official documentation for the symptomatic relief of mild to moderate pain, which includes headache.

---

Q: What is the L in Algifor-L supposed to mean?

The 'L' in Algifor-L refers to the L-Lysinate component of the active ingredient, Ibuprofen L-Lysinate. L-Lysinate is the specialized salt form of ibuprofen chemically combined with the amino acid L-Lysine.

---

Q: Can taking Algifor-L cause stomach discomfort or indigestion?

Official product information lists gastrointestinal discomfort, including nausea and abdominal pain, as an uncommon undesirable effect. Official usage guidelines advise taking the medicine with food for individuals who have a history of a sensitive stomach.

---

Q: Is it common to feel dizzy or drowsy after taking Algifor-L?

Official product information notes the potential for central nervous system effects such as dizziness or fatigue. Regulatory documents advise caution regarding driving or operating machinery when these effects are experienced.

---

Q: Does Algifor-L carry a warning about risk for kidney problems?

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) carry a documented risk of potentially affecting kidney function. Official warnings advise that caution should be exercised in patients with dehydration or pre-existing renal (kidney) impairment.

---

Q: Is Algifor-L generally considered safe for use while breastfeeding?

Published data regarding the active compound indicates that it passes into breastmilk at extremely low levels, suggesting compatibility with breastfeeding.

---

Q: Can elderly patients use Algifor-L without special considerations?

Official labeling states that older adult patients have a documented increased risk of experiencing severe adverse effects, especially gastrointestinal bleeding. Use in this population requires mandated caution.

---

Q: Why are people with severe kidney failure generally advised not to use Algifor-L?

The medicine is contraindicated (restricted from use) in cases of severe kidney failure. This is because the body primarily excretes the medicine's metabolites through the urine, and impaired kidney function may lead to accumulation.

---

Q: Does the scientific evidence show that Algifor-L is better absorbed than regular ibuprofen?

Pharmacokinetic studies indicate that the L-Lysinate salt formulation facilitates a more rapid rate of absorption compared to standard Ibuprofen acid when taken in a fasted state. This is measured by the time required to reach the peak concentration (Tmax) of the drug in the bloodstream.

---

Q: Is it normal to see the pain return before the next dose is due?

Regulatory documents indicate that the official dose interval is a minimum of four to six hours, which aligns with the typical duration of the medicine’s pain relief effect. This time frame is based on the known pharmacodynamics of the active compound.

---

Q: What is the difference between the active ingredient in Algifor-L and aspirin?

Both medicines belong to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, but the active ingredient in Algifor-L, Ibuprofen L-Lysinate, is a propionic acid derivative, which is a different chemical subclass from aspirin.

---

Q: What are the warnings about driving or operating machinery while using Algifor-L?

Because of the potential for effects such as dizziness, visual disturbances, or fatigue, official regulatory documents caution that the medicine may have a minor influence on the ability to drive or operate machinery.

---

Q: Does Algifor-L affect fertility or planning a pregnancy?

Official regulatory information states that, as with other NSAIDs, long-term or high-dose use of the active compound is known to affect ovulation. This effect may be transient and should be considered by women who are planning a pregnancy.

---

Q: Do any official documents discuss the long-term safety of Algifor-L?

Official regulatory documents emphasize that undesirable effects are minimized by adhering to the minimum effective dose for the shortest possible duration. This guidance is based on risks documented with prolonged use.

---

Q: Can Algifor-L be used for dental pain after a procedure?

The active compound has been examined in short-term trials for pain associated with acute episodes, including pain following dental surgery.

---

Q: Is Algifor-L approved for pain associated with common colds or flu?

Yes, the active compound is indicated for the relief of feverishness and other symptoms commonly associated with common colds and influenza.

---

Q: Is it true that Algifor-L may increase the risk of bleeding?

Official labeling documents a risk of potentially fatal gastrointestinal bleeding, ulceration, or perforation. This risk is noted, particularly when the medicine is used for prolonged periods or at high doses.

---

Q: Can Algifor-L be used for fever reduction?

Yes, one of the fundamental purposes of the medicine, alongside pain and inflammation relief, is to provide an antipyretic (fever-reducing) effect.

---

Q: Is there any research on Algifor-L specifically for muscle soreness after exercise?

Studies focusing on the core compound, Ibuprofen, have examined its use following physical activity. Research indicates that a moderate dose did not appear to affect ratings of muscle soreness or impair muscle growth.

How to Store and Dispose of Algifor-L?

Algifor-L (ibuprofen L-Lysinate) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

---

Official Storage Conditions

The medicine is required to be stored at room temperature, typically defined as a range of 15 C to 25 C. Storage must not exceed 25 C. The product should be stored in a manner that provides protection from light and moisture.

Storage Requirement	Official Condition
Temperature	15 C to 25 C (Room Temperature)
Protection	Keep out of sight and reach of children.
Stability	Do not use after the expiration date (EXP).

Disposal Requirements

Official labeling mandates that disposal of unused or expired Algifor-L must be in accordance with local regulations for pharmaceutical waste. The product must not be disposed of via household waste or wastewater systems as it is classified as posing a risk to the environment.